Last reviewed · How we verify
Human Growth Hormone
At a glance
| Generic name | Human Growth Hormone |
|---|---|
| Also known as | Human Growth Hormone (HGH), Somatotropin, Omnitrope, Norditropin, Humatrope |
| Sponsor | Center for Human Reproduction |
| Drug class | Standardized Insect Venom Allergenic Extract [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (PHASE3)
- Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
- Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (PHASE3)
- Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment (PHASE2)
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Growth Hormone CI brief — competitive landscape report
- Human Growth Hormone updates RSS · CI watch RSS
- Center for Human Reproduction portfolio CI